title: Interferon and cyclosporin A in the treatment of fulminant viral hepatitis.
abstract: The prognosis of fulminant hepatitis due to non-A, non-B virus infection and acute reactivation of hepatitis B virus in HB carriers is generally poor, and the treatment of choice in Western countries is recognized as liver transplantation. In countries such as Japan where liver transplantation is not readily available, however, these intractable types of fulminant hepatitis have to be treated medically. Based on the assumption that persistent replication of causal viruses and enhanced host immune responses, especially cellular immunity, to eradicate the viruses are the key mechanism in progressive liver cell destruction and the poor prognosis, we attempted a combination treatment with interferon and cyclosporin A for these types of fulminant viral hepatitis. Subjects in the present study consisted of 1 patient with acute severe hepatitis without coma and 13 patients with coma (13 with fulminant hepatic failure) due to non-A, non-B virus and acute reactivation of hepatitis B virus. The patients were given interferon-beta, 300 x 10(4) U daily, and cyclosporin A, at an initial dose of 3 mg/kg, with tapering. Fourteen patients with coma received artificial liver support that we devised. The patient with acute severe hepatitis survived, showing histologically remarkable liver regeneration. Eight of the 14 patients with hepatic coma, all of whom were indications for liver transplantation according to the criteria of the King's College group, survived. Decreased transaminase level, increased liver volume, and histological liver regeneration were observed in all the survivors. The combination of interferon and cyclosporin A is worth attempting in fulminant hepatitis caused by non-A, non-B virus and acute reactivation of hepatitis B virus in HB carriers.
authors.affiliation: Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yoshiba
authors.forename: K
authors.initials: K
authors.lastname: Sekiyama
authors.forename: K
authors.initials: K
authors.lastname: Inoue
authors.forename: R
authors.initials: R
authors.lastname: Fujita
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006501:Hepatic Encephalopathy / Q000473:pathology / Q000628:therapy*; D006509:Hepatitis B / Q000628:therapy; D006526:Hepatitis C / Q000628:therapy; D016751:Hepatitis E / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007223:Infant; D016899:Interferon-beta / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis
chemical_list: D016899:Interferon-beta; D016572:Cyclosporine